Hammerman, A. et al. 2015. The ‘real-life’ impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: A large Israeli retrospective cohort study. Acta Oncologica. 54, 2 (Feb. 2015), 164–170. DOI:https://doi.org/10.3109/0284186X.2014.958532.